Medical Devices Investors & VC Firms in Cambridge

24 firms in this list, with a median first check of $1M. 4 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
F- F-Prime Capital Partners APCBCXDJ104 people · Leads rounds	88🔒	Cambridge	US	Pre-Seed–Late Stage	$3M – $10M	+ Add to CRM
E1 E14 Fund CCSCAKAG33 people · Leads rounds	88🔒	Cambridge	US	Pre-Seed–Series A	$1M – $5M	+ Add to CRM
SA Sanofi Ventures KMAB27 people · Leads rounds	88🔒	Cambridge	US	Seed–Late Stage	$5M	+ Add to CRM
AM Amadeus Capital Partners AACDMCNK34 people · Follows rounds	88🔒	London	GB	Pre-Seed–Late Stage	$50K – $12.7M	+ Add to CRM
AT Atlas Venture BBDGJRJF24 people · Follows rounds	88🔒	Cambridge	US	Seed–Late Stage	$500K – $1M	+ Add to CRM
SA Safar Partners GSBMRMAC20 people	88🔒	Cambridge	US	Seed–Late Stage	—	+ Add to CRM
TA Takeda Ventures JKAAASAM22 people · Follows rounds	88🔒	Cambridge	US	Pre-Seed–Late Stage	$1M – $5M	+ Add to CRM
MA Martlet Capital DITHAWDI8 people	88🔒	Cambridge	GB	Pre-Seed–Series A	$317.5K	+ Add to CRM
DE Delos Capital HCTXEHLC12 people	88🔒	Cambridge	US	Seed–Late Stage	—	+ Add to CRM
SY SyndicateRoom GSTBFOMG15 people · Follows rounds	88🔒	Cambridge	GB	Pre-Seed–Series A	—	+ Add to CRM
IA Iaso Ventures WMJRMGMF12 people	88🔒	Cambridge	US	Seed–Series A	—	+ Add to CRM
MC MC Healthcare Ventures SOJMTO3 people	88🔒	Cambridge	US	Seed–Series A	—	+ Add to CRM
MR MRL Ventures Fund PDKKODTF5 people · Leads rounds	88🔒	Cambridge	US	Seed–Series B	$25M	+ Add to CRM
B- B-FLEXION APNLSAFW13 people	88🔒	St. Helier	US	Seed–Late Stage	$500K	+ Add to CRM
BL Blackstone Life Sciences NGABBGCF9 people	88🔒	New York	US	Series A–Late Stage	$20M – $60M	+ Add to CRM
UN University of Cambridge Enterprise CMAWCGMS10 people	88🔒	Cambridge	GB	Pre-Seed–Late Stage	—	+ Add to CRM
ET ETCapital MRJGDG3 people · Follows rounds	88🔒	Cambridge	GB	Pre-Seed–Series A	$100K – $952.5K	+ Add to CRM
ST Start Codon ITI2 people	88🔒	Cambridge	GB	Pre-Seed–Seed	—	+ Add to CRM
SA Saisei Ventures HSJYSKSD5 people	88🔒	Cambridge	US	Pre-Seed–Growth	—	+ Add to CRM
HE HealthCare Ventures, LLC AL1 person	88🔒	Cambridge	US	Series A–Late Stage	$1M – $20M	+ Add to CRM
TT TTP Ventures	88🔒	Cambridge	GB	Seed–Late Stage	—	+ Add to CRM
CA Cambridge Capital Group	88🔒	Cambridge	GB	Pre-Seed–Growth	—	+ Add to CRM
QI Qiming Venture Partners USA Follows rounds	88🔒	Cambridge	US	Seed–Series A	—	+ Add to CRM
YO Yonjin Venture LLC DWDM2 people	88🔒	Cambridge	US	Seed–Series B	—	+ Add to CRM

F-Prime Capital Partners

CambridgePre-Seed–Late Stage$3M – $10M

APCBCXDJ104 people

E14 Fund

CambridgePre-Seed–Series A$1M – $5M

CCSCAKAG33 people

Sanofi Ventures

CambridgeSeed–Late Stage$5M

KMAB27 people

Amadeus Capital Partners

LondonPre-Seed–Late Stage$50K – $12.7M

AACDMCNK34 people

Atlas Venture

CambridgeSeed–Late Stage$500K – $1M

BBDGJRJF24 people

Safar Partners

CambridgeSeed–Late Stage

GSBMRMAC20 people

Takeda Ventures

CambridgePre-Seed–Late Stage$1M – $5M

JKAAASAM22 people

Martlet Capital

CambridgePre-Seed–Series A$317.5K

DITHAWDI8 people

Delos Capital

CambridgeSeed–Late Stage

HCTXEHLC12 people

SyndicateRoom

CambridgePre-Seed–Series A

GSTBFOMG15 people

Iaso Ventures

CambridgeSeed–Series A

WMJRMGMF12 people

MC Healthcare Ventures

CambridgeSeed–Series A

SOJMTO3 people

MRL Ventures Fund

CambridgeSeed–Series B$25M

PDKKODTF5 people

B-FLEXION

St. HelierSeed–Late Stage$500K

APNLSAFW13 people

Blackstone Life Sciences

New YorkSeries A–Late Stage$20M – $60M

NGABBGCF9 people

University of Cambridge Enterprise

CambridgePre-Seed–Late Stage

CMAWCGMS10 people

ETCapital

CambridgePre-Seed–Series A$100K – $952.5K

MRJGDG3 people

Start Codon

CambridgePre-Seed–Seed

ITI2 people

Saisei Ventures

CambridgePre-Seed–Growth

HSJYSKSD5 people

HealthCare Ventures, LLC

CambridgeSeries A–Late Stage$1M – $20M

AL1 person

TTP Ventures

CambridgeSeed–Late Stage

Cambridge Capital Group

CambridgePre-Seed–Growth

Qiming Venture Partners USA

CambridgeSeed–Series A

Yonjin Venture LLC

CambridgeSeed–Series B

DWDM2 people

Data sourced from public filings and firms' own websites — see our methodology.